• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.血清中卵巢癌标志物 HE4 的水平在妊娠期间降低,并随年龄增长而升高。
Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7. doi: 10.1016/j.ajog.2011.12.028. Epub 2011 Dec 30.
2
Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.人附睾蛋白 4(HE4)在波兰健康女性、孕妇和患有良性卵巢肿瘤女性中的参考范围。
Dis Markers. 2019 Aug 22;2019:3890906. doi: 10.1155/2019/3890906. eCollection 2019.
3
Human epididymis protein 4 reference intervals in a multiethnic asian women population.多民族亚洲女性人群中附睾蛋白4的参考区间
Asian Pac J Cancer Prev. 2012;13(12):6391-5. doi: 10.7314/apjcp.2012.13.12.6391.
4
Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people.年龄和绝经状态是影响血清附睾分泌蛋白4水平的重要因素:一项针对健康中国人的前瞻性横断面研究。
Chin Med J (Engl). 2020 Jun 5;133(11):1285-1291. doi: 10.1097/CM9.0000000000000785.
5
The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.考虑绝经状态的卵巢恶性肿瘤风险算法的效能:与 CA125 和 HE4 的比较。
J Gynecol Oncol. 2019 Nov;30(6):e83. doi: 10.3802/jgo.2019.30.e83.
6
Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.中国女性血清人附睾蛋白4(HE4)水平参考区间的测定。
J Ovarian Res. 2015 Nov 9;8:72. doi: 10.1186/s13048-015-0201-z.
7
Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.分析不同组织学亚型上皮性卵巢癌及其他恶性肿瘤患者血清 HE4 水平。
Tumour Biol. 2021;43(1):355-365. doi: 10.3233/TUB-211546.
8
The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.血清 HE4 在 CA125 升高的卵巢疾病中的鉴别诊断价值及临床意义。
Arch Gynecol Obstet. 2020 May;301(5):1219-1225. doi: 10.1007/s00404-020-05527-0. Epub 2020 Apr 7.
9
Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.CA125、HE4 和 ROMA 指数在卵巢癌诊断中的比较。
Curr Probl Cancer. 2019 Apr;43(2):135-144. doi: 10.1016/j.currproblcancer.2018.06.001. Epub 2018 Jun 12.
10
Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.CA125、HE4及ROMA指数在卵巢癌中的诊断效能
Eur J Gynaecol Oncol. 2015;36(4):457-62.

引用本文的文献

1
Tumor biomarkers HE4 and CA125 alongside enhanced computed tomography imaging in assessing lymph node metastasis in endometrial cancer.肿瘤生物标志物HE4和CA125联合增强计算机断层扫描成像在评估子宫内膜癌淋巴结转移中的应用
Bioinformation. 2024 Nov 30;20(11):1453-1460. doi: 10.6026/9732063002001453. eCollection 2024.
2
Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management.用于肺癌患者纵向管理的新型液体活检生物标志物组合指数的开发与验证
J Liq Biopsy. 2024 Sep 10;6:100167. doi: 10.1016/j.jlb.2024.100167. eCollection 2024 Dec.
3
Diagnostic role of urine human epididymis protein 4 in ovarian cancer.尿人附睾蛋白 4 在卵巢癌中的诊断作用。
Biochem Med (Zagreb). 2024 Oct 15;34(3):030502. doi: 10.11613/BM.2024.030502.
4
The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.CA125 和 HE4 作为 BRCA 突变上皮性卵巢癌患者临床预后标志物的有效性。
J Gynecol Oncol. 2024 Nov;35(6):e80. doi: 10.3802/jgo.2024.35.e80. Epub 2024 Apr 16.
5
Effect of Serum Level of Human Epididymis Protein 4 and Interleukin-6 as Biomarkers in Patients with Adnexal Mass.血清人附睾蛋白 4 和白细胞介素-6 作为附件包块患者生物标志物的效果。
Arch Razi Inst. 2022 Oct 31;77(5):1659-1671. doi: 10.22092/ARI.2022.358329.2194. eCollection 2022 Oct.
6
Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features.血清CA125和HE4作为检测子宫内膜癌及相关高危特征的生物标志物。
Diagnostics (Basel). 2022 Nov 17;12(11):2834. doi: 10.3390/diagnostics12112834.
7
Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets.上皮性卵巢癌中的环状RNA:从生物标志物到治疗靶点
Cancers (Basel). 2022 Nov 21;14(22):5711. doi: 10.3390/cancers14225711.
8
HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.HE4 组织表达作为低风险/低级别子宫内膜样子宫内膜癌的潜在预后标志物:综述。
Curr Oncol. 2022 Nov 10;29(11):8540-8555. doi: 10.3390/curroncol29110673.
9
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.血清生物标志物panel 诊断在胰腺导管腺癌中的应用:可溶性白细胞介素、IFN-γ、TNF-α 和 PD-1/PD-L1 与已建立的血清肿瘤标志物的临床效用比较。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2463-2474. doi: 10.1007/s00432-022-04112-z. Epub 2022 Jun 23.
10
The Association between Human Epididymis Secretory Protein 4 and Metabolic Syndrome.人类附睾分泌蛋白4与代谢综合征之间的关联
J Clin Med. 2022 Apr 22;11(9):2362. doi: 10.3390/jcm11092362.

本文引用的文献

1
Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.评估盆腔包块患者中卵巢恶性肿瘤风险算法的诊断准确性。
Obstet Gynecol. 2011 Aug;118(2 Pt 1):280-288. doi: 10.1097/AOG.0b013e318224fce2.
2
HE4: a new potential early biomarker for the recurrence of ovarian cancer.人附睾蛋白4:一种用于卵巢癌复发的新的潜在早期生物标志物。
Tumour Biol. 2010 Apr;31(2):113-9. doi: 10.1007/s13277-009-0015-y. Epub 2010 Jan 23.
3
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.用于鉴别附件包块患者良恶性病例的血清生物标志物组合。
Gynecol Oncol. 2010 Jun;117(3):440-5. doi: 10.1016/j.ygyno.2010.02.005. Epub 2010 Mar 24.
4
Current state of biomarker development for clinical application in epithelial ovarian cancer.上皮性卵巢癌临床应用中生物标志物的研究现状。
Gynecol Oncol. 2010 Feb;116(2):240-5. doi: 10.1016/j.ygyno.2009.09.041. Epub 2009 Oct 31.
5
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.血清人附睾蛋白4(HE4)浓度可区分恶性卵巢肿瘤与卵巢子宫内膜异位囊肿。
Br J Cancer. 2009 Apr 21;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. Epub 2009 Mar 31.
6
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性,以及所检测癌症的分期分布:英国卵巢癌筛查协作试验(UKCTOCS)患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
7
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.一种利用人附睾蛋白4(HE4)和癌抗原125(CA125)预测盆腔肿块患者卵巢癌的新型多标志物生物测定法。
Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.
8
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.个人特征对卵巢癌高危绝经后健康女性血清CA125、间皮素和HE4水平的影响。
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7. doi: 10.1158/1055-9965.EPI-08-0150.
9
Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.影响伊朗绝经后健康女性血清CA125和CA15-3浓度的因素
Pathol Oncol Res. 2007;13(4):360-4. doi: 10.1007/BF02940317. Epub 2007 Dec 25.
10
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.使用多种新型肿瘤生物标志物检测盆腔肿块患者的卵巢癌。
Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. Epub 2007 Dec 3.

血清中卵巢癌标志物 HE4 的水平在妊娠期间降低,并随年龄增长而升高。

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

机构信息

Center for Biomarkers and Emerging Technologies, Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA.

出版信息

Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7. doi: 10.1016/j.ajog.2011.12.028. Epub 2011 Dec 30.

DOI:10.1016/j.ajog.2011.12.028
PMID:22301440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3987114/
Abstract

OBJECTIVE

The purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women.

STUDY DESIGN

HE4 levels were measured in healthy women and analyzed by age, menopausal status, and pregnancy status. Upper 95th percentiles were determined for normal ranges.

RESULTS

Serum samples from 1101 healthy women and 67 pregnant women were analyzed. Above the age of 40 years significant elevations in HE4 concentrations emerged with advancing age. The upper 95th percentile for HE4 levels was 89 pmol/L for premenopausal women, 128 pmol/L for postmenopausal women, and 115 pmol/L for all women. There was a significant difference in the median serum HE4 levels in premenopausal women (46.6 pmol/L) compared with postmenopausal women (57.6 pmol/L; P < .001). In pregnant women, median HE4 concentrations were significantly lower than their premenopausal counterparts (P < .001).

CONCLUSION

HE4 serum concentrations vary significantly on the basis of age. These variations must be considered when the upper limit of normal for HE4 is determined.

摘要

目的

本研究旨在建立健康女性人附睾蛋白 4(HE4)血清水平的正常范围。

研究设计

测量健康女性的 HE4 水平,并按年龄、绝经状态和妊娠状态进行分析。确定正常范围的 95%上限。

结果

分析了 1101 名健康女性和 67 名孕妇的血清样本。年龄超过 40 岁时,HE4 浓度随着年龄的增长而显著升高。绝经前女性的 HE4 水平 95%上限为 89pmol/L,绝经后女性为 128pmol/L,所有女性为 115pmol/L。绝经前女性(46.6pmol/L)与绝经后女性(57.6pmol/L;P<0.001)的中位血清 HE4 水平存在显著差异。孕妇的中位 HE4 浓度明显低于绝经前女性(P<0.001)。

结论

HE4 血清浓度随年龄显著变化。在确定 HE4 的正常上限时,必须考虑这些变化。